Factor H autoantibodies in membranoproliferative glomerulonephritis

被引:64
|
作者
Goodship, Timothy H. J. [1 ,2 ]
Pappworth, Isabel Y. [1 ,2 ]
Toth, Tibor [3 ]
Denton, Mark [4 ]
Houlberg, Kris [5 ]
McCormick, Frances [6 ]
Warland, David [7 ]
Moore, Iain [1 ,2 ]
Hunze, Eva-Maria [1 ,2 ]
Staniforth, Scott J. [1 ,2 ]
Hayes, Christine [1 ,2 ]
Cavalcante, Danielle Paixao [8 ]
Kavanagh, David [1 ,2 ]
Strain, Lisa [9 ]
Herbert, Andrew P. [10 ]
Schmidt, Christoph Q. [10 ]
Barlow, Paul N. [10 ]
Harris, Claire L. [8 ]
Marchbank, Kevin J. [1 ,2 ]
机构
[1] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England
[2] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England
[3] N Bristol NHS Trust, Southmead Hosp, Dept Cellular Pathol, Bristol, Avon, England
[4] Mater Misericordiae Univ Hosp, Dept Nephrol, Dublin, Ireland
[5] Plymouth Hosp NHS Trust, Derriford Hosp, Dept Renal Med, Plymouth, Devon, England
[6] Plymouth Hosp NHS Trust, Derriford Hosp, Dept Pathol, Plymouth, Devon, England
[7] Dorset Cty Hosp NHS Fdn Trust, Renal Dept, Dorchester, Dorset, England
[8] Cardiff Univ, Sch Med, Inst Infect & Immun, Cardiff, S Glam, Wales
[9] Newcastle Upon Tyne Hosp NHS Fdn Trust, No Mol Genet Serv, Newcastle Upon Tyne, Tyne & Wear, England
[10] Univ Edinburgh, Sch Chem, Edinburgh, Midlothian, Scotland
关键词
Factor H; Complement; MPGN; Autoantibodies; HEMOLYTIC-UREMIC SYNDROME; DENSE DEPOSIT DISEASE; COMPLEMENT FACTOR-H; ALTERNATIVE PATHWAY; FACTOR-B; NEPHRITIC FACTOR; MPGN-II; MUTATIONS; C3; PREDISPOSE;
D O I
10.1016/j.molimm.2012.05.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Factor H autoantibodies are found in similar to 10% of aHUS patients. Most are associated with complete deficiency of factor H related proteins 1/3 and bind to the C terminal recognition domain. MPGN, like aHUS, is characterised by complement activation. In this study we, therefore, examined the hypothesis that factor H autoantibodies are associated with MPGN. We screened sera from 16 MPGN patients and 100 normal controls using ELISA and detected strongly positive IgG factor H autoantibodies in 2 patients. One patient had type II (DDD) MPGN (male aged 24 yrs) with C3NeF and the other type I (female aged 26 yrs) with no detectable C3NeF. We identified the binding site of the autoantibodies using small SCR domain fragments in the ELISA and showed that the autoantibodies in both patients bound predominately to the N terminal complement regulatory domain of factor H. We measured CFHR1/3 copy number using MLPA and showed that both patients had 2 copies of CFHR1 and 3. Finally, we examined the functionality of detected factor H autoantibodies using purified patient IgG and observed increased haemolysis when purified IgG from both patients was added to normal human sera prior to incubation with rabbit red blood cells. Thus, in a cohort of MPGN patients we have found a high titre of functionally significant factor H autoantibodies in two patients with MPGN. Antibody depleting therapy may have a role in such patients and we suggest that screening for factor H autoantibodies should be undertaken in all patients with MPGN. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:200 / 206
页数:7
相关论文
共 50 条
  • [31] PORCINE MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS TYPE-II - AN AUTOSOMAL RECESSIVE DEFICIENCY OF FACTOR-H
    JANSEN, JH
    HOGASEN, K
    GRONDAHL, AM
    VETERINARY RECORD, 1995, 137 (10) : 240 - 244
  • [32] Familial membranoproliferative glomerulonephritis type I associated with a functionally significant mutation in complement factor H
    Wong, Edwin
    Anderson, Holly
    Challis, Rachel
    Herbert, Andrew
    Barlow, Paul
    Fluck, Nick
    Humphrey, Ann
    MacLeod, Alison
    Marchbank, Kevin
    Kavanagh, David
    Goodship, Tim
    IMMUNOBIOLOGY, 2012, 217 (11) : 1171 - 1171
  • [33] Porcine membranoproliferative glomerulonephritis (MPGN) type II is prevented and reversed by factor H substitution therapy
    Hogåsen, K
    Jansen, JH
    MOLECULAR IMMUNOLOGY, 1999, 36 (4-5) : 305 - 305
  • [34] Porcine membranoproliferative glomerulonephritis (MPGN) type II is reversed by factor H substitution therapy.
    Hogasen, K
    Jansen, JH
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A2206 - A2206
  • [35] Prevention of C5 activation ameliorates membranoproliferative glomerulonephritis associated with factor H deficiency
    Pickering, MC
    Warren, J
    Rose, K
    Carlucci, F
    Moss, J
    Wang, Y
    Walport, MJ
    Cook, HT
    Botto, M
    MOLECULAR IMMUNOLOGY, 2006, 43 (1-2) : 140 - 141
  • [36] HEREDITARY PORCINE MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS TYPE-II IS CAUSED BY FACTOR-H DEFICIENCY
    HOGASEN, K
    JANSEN, JH
    MOLLNES, TE
    HOVDENES, J
    HARBOE, M
    JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (03): : 1054 - 1061
  • [37] SECONDARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
    RENNKE, HG
    HARRINGTON, JT
    SINGH, AK
    LEVEY, AS
    MADIAS, NE
    PEREIRA, B
    KING, A
    KIDNEY INTERNATIONAL, 1995, 47 (02) : 643 - 656
  • [38] MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS AND PREGNANCY
    JORNET, AR
    VALLES, M
    ESPINEL, E
    CODINA, S
    FERRER, E
    PIERA, L
    MEDICINA CLINICA, 1984, 82 (13): : 575 - 577
  • [39] MEMBRANOPROLIFERATIVE AND LOBULAR GLOMERULONEPHRITIS
    MANDALENAKIS, N
    MENDOZA, N
    PIRANI, CL
    POLLAK, VE
    AMERICAN JOURNAL OF PATHOLOGY, 1971, 62 (02): : A56 - +
  • [40] MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS IN MALAYSIA
    WANG, F
    PRATHAP, K
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1978, 8 (02): : 244 - 244